CFH rs3916965: Understanding Your Genetic Variant
The rs3916965 variant is a single nucleotide polymorphism located within the CFH gene, which plays a critical role in the body's immune system. Research has identified this variant as part of a group of genetic markers associated with an increased susceptibility to age-related macular degeneration (AMD).
What each genotype means
Baseline risk profile
This genotype is considered the major allele at this position within the CFH gene. Research indicates that this marker is part of larger genetic haplotypes associated with susceptibility to age-related macular degeneration, though its individual contribution is part of a complex genetic landscape. You should discuss your overall eye health and family history with an eye care professional.
This is a common genotype found across global populations, consistent with the reported minor allele frequency of 0.20-0.35 for this variant.
Intermediate risk profile
Carrying one copy of the minor allele at this position is associated with the genetic architecture of the CFH gene, which is linked to age-related macular degeneration risk. Because this variant is an intronic marker, it is often studied as part of a haplotype rather than as a direct cause of disease. Regular comprehensive eye exams are recommended for monitoring long-term vision health.
This heterozygous genotype is frequently observed in populations of European descent, reflecting the common nature of this variant.
Elevated risk profile
This genotype represents the homozygous minor allele state at this CFH locus. While this marker is associated with susceptibility haplotypes for choroidal neovascularization and macular atrophy, it is one of many genetic and environmental factors that influence eye health. Please consult with an ophthalmologist to discuss appropriate screening schedules based on your personal and family history.
This genotype is less common than the others but is present at significant frequencies in many global populations.
What is rs3916965?
The rs3916965 variant is a specific genetic change, or single nucleotide polymorphism (SNP), located within the CFH gene. This gene is situated on the long arm of chromosome 1 at position 1q31.3. As an intronic marker, rs3916965 does not directly alter the protein sequence of the complement factor H protein. Instead, it serves as a genetic signpost that is often inherited alongside other variations in the CFH region. These clusters of variants, known as haplotypes, are studied by researchers to understand how they influence the regulation of the complement system, a part of the immune system that helps protect the body from infection and inflammation. Because it is located in a non-coding region, its primary significance lies in its statistical association with specific health conditions rather than a direct functional change to the protein itself.
The Role of the CFH Gene
The CFH gene provides the instructions for creating the complement factor H protein. This protein is a vital regulator of the alternative pathway of the complement system, which is a component of the innate immune response. By acting as a control mechanism, complement factor H prevents the immune system from becoming overactive and damaging the body's own healthy tissues. In the eye, particularly within the retinal pigment epithelium and the choroid, this regulation is essential for maintaining tissue health. When the complement system is not properly regulated, it can lead to chronic inflammation and the accumulation of deposits, which are hallmark features of age-related macular degeneration. Variations in the CFH gene, including those linked to rs3916965, are thought to potentially attenuate this inhibitory function, thereby increasing the risk of complement-mediated damage to the delicate structures of the retina.
Research and Evidence Strength
The association between CFH variants and age-related macular degeneration (AMD) is a well-documented area of ophthalmic genetics. Research has consistently identified the CFH region as a major susceptibility locus for AMD, a condition that affects the macula and impairs central vision. The evidence for rs3916965 specifically is considered limited in terms of its individual functional impact, as it is often studied as part of a broader haplotype that contributes to the risk of choroidal neovascularization and macular atrophy. It is important to note that genetic associations can vary significantly by ancestry; for example, while certain CFH variants are strongly linked to AMD in populations of European descent, these associations may not be observed or may be much weaker in other populations, such as those of Japanese descent. Consequently, while the CFH gene is a confirmed risk factor, the specific contribution of rs3916965 is part of a complex, polygenic landscape.
Understanding Your Results
If you have received information about your rs3916965 genotype, it is important to view this in the context of overall eye health. This variant is a marker of susceptibility, not a diagnostic tool. Having a specific genotype does not mean you will develop macular degeneration, nor does the absence of it guarantee protection. AMD is a multifactorial condition influenced by a combination of genetics, environmental factors, and lifestyle choices, such as smoking and diet. You cannot use this information to diagnose yourself or predict a clinical outcome. If you are concerned about your vision or your family history of eye disease, the most appropriate step is to consult with an eye care professional, such as an ophthalmologist or optometrist. They can provide comprehensive eye exams and personalized advice based on your clinical presentation, which is far more informative than any single genetic marker.
How common is this variant?
The minor allele frequency for rs3916965 is approximately 0.20 to 0.35 across global populations, indicating that the variant is relatively common.
Frequently asked questions
Does having the rs3916965 variant mean I will get macular degeneration?
No. This variant is only one of many factors that contribute to the risk of developing age-related macular degeneration. Many people with this variant never develop the condition, and it is influenced by many other genetic and environmental factors.
Can I change my risk associated with this CFH variant?
While you cannot change your genetics, you can manage modifiable risk factors for eye health. Maintaining a healthy diet, avoiding smoking, and scheduling regular comprehensive eye exams are recommended strategies for supporting long-term vision health.
Is this variant the same as the Y402H variant?
No, rs3916965 is a distinct variant from the well-known Y402H (rs1061170) variant. Both are located within the CFH gene region and are studied for their roles in macular degeneration, but they are separate genetic markers.
Should I take supplements if I have this genotype?
You should not start any supplements based on your genetic results alone. Please discuss your eye health and any potential nutritional needs with your ophthalmologist or a qualified healthcare provider.
Sources & further reading
Educational information only, last refreshed 10/9/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs3916965?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CFH
This variant in the complement factor H gene is associated with altered regulation of the alternative complement pathway and increased susceptibility to age-related macular degeneration.
This regulatory variant in the CFH locus is linked to complement system dysregulation and is a recognized genetic risk factor for age-related macular degeneration.
Intronic single nucleotide variant in the CFH region associated with susceptibility to age-related macular degeneration (AMD).
Common variant in the CFH locus strongly associated with risk of age-related macular degeneration (AMD).
Genomic marker in CFH frequently co-inherited in haplotypes modulating risk of late-stage visual loss from macular degeneration.
Intergenic/intronic variant within the CFH cluster contributing to phenotypic variation in retinal complement activation.